Details for 2019856433

Up to date per 03.04.2026

Actions

Title / Product Name

VERWENDUNG VON VON TUMORINFILTRIERENDEN LYMPHOZYTEN ZUR BEHANDLUNG VON NSCLC PATIENTEN DIE GEGEN ANTI-PD1 ANTIKÖRPERTHERAPIE RESISTENT SIND

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2019856433

EP Publication Number

3843759

E-Number

1656483

Language

PCT Number

US19049384

Publication Date

07.07.2021 A

14.02.2024 B1

Registration Date

14.02.2024

AT Publication Date

15.03.2024

Application Date

03.09.2019

Registration Number

Priorities

31.08.2018

201862725976 P

04.09.2018

201862726919 P

IPC

A61K 35/17 20150101AFI20231109BHEP

Maximum Duration of Protection

03.09.2039

Owner

Iovance Biotherapeutics, Inc.825 Industrial Road Suite 400 San Carlos, CA 94070US

Representative

Babeluk Patentanwälte GmbHFlorianigasse 26/31080 WienAT

Inventor

FARDIS, Maria105 Aberdeen Drive San Carlos, CA 94070US

NATARAJAN, Arvind174 Smoke Rise Road Basking Ridge, NJ 07920US

Information about Fees